Medical Marketing and Media

RSS | Login | Register

Washington Insider Articles

As I See It: The threat to FDA independence

James G. Dickinson May 01, 2012

There are claims that a politically independent FDA belongs in "a world that doesn't exist any more"

Woodcock: Hill should hold line on standards

James G. Dickinson May 01, 2012

FDA drugs director Janet Woodcock told the House Energy and Commerce Committee in March that Congress should not change the standards for determining a therapy's safety and effectiveness

FDA work integrity rises, survey says

James G. Dickinson May 01, 2012

A Union of Concerned Scientists survey of 997 FDA scientists suggests that agency leaders are helping to boost scientific integrity but still are beset by interference from special interests.

As I See It: Ghostwriting

Paul Thacker April 01, 2012

Apparently, unless the rules explicity prohibit a specific type of unethical behavior, you're OK

Congress sets its sights on bringing down IPAB

Matthew Arnold April 01, 2012

Congressional Republicans—and a few Democrats—are pressing the attack on the Independent Payment Advisory Board for Medicare.

Project FDA spurs industry efficiency

James G. Dickinson April 01, 2012

Former FDA commissioner Andrew von Eschenbach has joined the Manhattan Institute to head up its Project FDA initiative.

As I See It: Global systems for quality and safety

Peter Pitts March 01, 2012

It's time for a regulatory Marshall plan to help build global systems for quality and safety

Sens. Klobuchar, Collins push drug-shortage bill

James G. Dickinson March 01, 2012

U.S. senators Amy Klobuchar and Susan Collins are trying to quickly pass a bill addressing the growing drug shortage problem

User-fee inaction could cause logjam

James G. Dickinson March 01, 2012

Congressional inaction could lead to a huge new products-review backlog, according to FDA Matters editor Steven Grossman.

As I See It: Political interference in FDA

James G. Dickinson February 01, 2012

Political interference in FDA's scientific decisions is growing, well-hidden phenomenon

« Previous

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.